This site is intended for healthcare professionals

BeiGene announces FDA acceptance and priority review of supplemental NDA for Brukinsa in marginal zone lymphoma.

Read time: 1 mins
Last updated:28th Jun 2021
Published:22nd May 2021
BeiGene, Ltd. announced that the FDA has accepted a supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy and granted priority review.
Condition: Marginal Cell Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest